Citadel Advisors »

Galmed Pharmaceuticals shares owned by Citadel Advisors

Quarter-by-quarter ownership of Galmed Pharmaceuticals (GLMD) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Galmed Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Galmed Pharmaceuticals held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Galmed Pharmaceuticals by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $71k 51k 1.41

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Spdr Gold Tr Gold Shs Call Option (GLD)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
Strategy Cl A New Call Option (MSTR)
Alphabet Cap Stk Cl A Call Option (GOOGL)
UnitedHealth Call Option (UNH)
Palantir Technologies Cl A Call Option (PLTR)
Netflix Call Option (NFLX)

View all positions for Citadel Advisors

Top funds holding Galmed Pharmaceuticals

Citadel Advisors
Morgan Stanley
Two Sigma Investments
UBS Group
Sontag Advisory
TSFG
SBI Securities
Federation des caisses Desjardins du Quebec
Wells Fargo & Company
Advisor Group Holdings
Hanson McClain Advisors
TD Waterhouse Canada
Dogwood Wealth Management
Zrc Wealth Management

View all funds holding Galmed Pharmaceuticals